There are about 36818 clinical studies being (or have been) conducted in China. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The purpose of this study is to evaluate the efficacy and safety of Microport sirolimus drug coated balloon catheter for the treatment of coronary bifurcation lesions.
Epilepsy is a common neurological disease, manifested in the sudden abnormal discharge of neurons leading to short-term brain dysfunction, has become the neurology after headache the second most common disease. In China, the prevalence of epilepsy is about 4.7-8.5 per 1,000, and more than 400,000 new cases of epilepsy are developed each year. Of these, 30% of patients were treated with ineffective medication, developing into a drug-incurable epilepsy that required surgery and other treatments. The most common type of epilepsy is temporal lobe epilepsy, while the common complication in temporal lobe epilepsy is hippocampal sclerosis, which often requires surgical removal. The incidence of inner temporal lobe epilepsy associated with hippocampal sclerosis is increasing, but its exact cause and specific pathogenesis are still unclear, so clarifying its pathogenesis will contribute to the understanding of temporal lobe epilepsy and the improvement of surgical procedures. This study is intended to get single-cell transcriptome as well as spatial transcriptome data of temporal lobe and hippocampus samples. By studying gene expression change associated with epilepsy and hippocampus sclerosis, we intended to find possible prognostic-related molecules and to deepen understanding of pathological changes in epilepsy at the molecular level.
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed and refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma
Endophthalmitis is also called vitreous inflammation. Broadly speaking, it refers to all kinds of serious intraocular inflammation, such as vitreitis, anterior chamber empyema and eye pain caused by intraocular infection, intraocular foreign body, tumor necrosis, severe non infectious uveitis, lens cortex allergy, etc. Clinically, it generally refers to infectious endophthalmitis caused by bacteria, fungi or parasites. According to the different ways of infection, it can be divided into exogenous endophthalmitis and endogenous endophthalmitis. Exogenous endophthalmitis is more common. When inflammation involves sclera or extraocular orbital tissue, it is called "panophthalmia". Endophthalmitis is a kind of serious intraocular inflammation which can lead to the loss of visual function. Early diagnosis and treatment is the key. Studies have found that the changes of cytokines in aqueous humor are helpful for the diagnosis of endophthalmitis. Okhrvai et al. Also pointed out that the application of PCR can reduce the diagnosis time of endophthalmitis. This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
In the fight against the epidemic, medical personnel need to wear protective equipment, such as N95 mask, face screen, goggles, latex gloves, waterproof isolation clothing, and have special requirements. Protection-related skin lesions after the use of protective equipment will affect the health and comfort of medical workers. In this study, a retrospective study was conducted on the front-line medical workers in the fight against COVID-19 using questionnaires, so as to understand the incidence, location and clinical manifestations of skin lesions caused by the use of protective equipment by medical workers. And analyze the causes of these skin damage, so as to develop the corresponding prevention and treatment countermeasures, select 170 cases that meet the research conditions, a randomized controlled experiment, divided into control group and experimental group: the control group is on the basis of three-level protection, did not use any preventive measures of health care workers. In the experimental group, skin related prevention was carried out on the basis of three-level protection. The specific interventions are as follows :(1) Focus on protecting exposed skin and making it locally dry. (2) Do a good job of facial moisturizing before work (at least 1 hour before wearing the mask), use moisturizing ointment, longer lasting and non-irritating cream or emulsion, such as vitamin E cream, Vaseline, avoid direct contact with the skin of the mask, choose the appropriate type of protective device; Reduce friction by sticking foam paste, hydrocolloid accessories, ampute and so on on good hair parts. However, it should be noted that it must be confirmed that the airtightness is good, and the primary purpose of the medical staff is to ensure the protective effect. (4) After work, avoid using irritant (such as hot water, exfoliating cream, etc.) to clean the face, and massage local skin with skin moisturizer; (5) In case of severe skin damage, treat as prescribed by the doctor; (6) After finishing the front-line work, "Questionnaire Star" was used to collect data, and all data were input into the statistical software for analysis to compare the index differences between the two groups.
Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer. Investigators initiated this phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.
Background: Experimental and cross-sectional evidence suggests that poor executive function can lead to heightened reactivity to food cues and perceived greater reward of unhealthy but palatable foods and subsequently lead to overeating or clinical eating disorders. This may be an important reason for the increasing trend of obesity in our society. Aims: This study will investigate the interrelationships among executive function, reactivity to food-related cues and eating style in young adults. In addition, this study will examine the influence of food environment and stress on reactivity to food-related cues and executive function and how executive function and reactivity to food-related cues would influence health risky behaviours in young adults. We will also conduct a pilot randomized control trial (RCT) to develop the culturally specific goal priming intervention for the Chinese adults and test its effect on decision-making for food choice among adults with low executive function. Design and subjects: This will be a three-wave cohort study in young adults who are recruited in their final-year of first post-secondary education and follow-up at six months and 12 months after their graduation. For the pilot RCT, a 2 (low vs. high executive function) x 2 (with vs. without goal priming intervention) will be used to test the effect of goal priming intervention on food choice. The goal priming intervention will be 5-min word-searching task to prime goals of healthy eating. Main outcome measures: Participants will be invited to complete a series on computerized tasks and other assessments online in each wave to assess their executive function, risk taking propensity, reactivity to food-related cues, perceived stress, exposure to food-related cues, eating style and other health-related behaviours. Structural equation modelling will be used to test the interrelationships among executive function, reactivity to food-related cues and eating style, among exposure to food-related cues, perceived stress and reactivity to food-related cues, and among executive function, reactivity to food-related cues, risk taking and adoption of health-related behaviours. For the pilot RCT, the effect of intervention on tendency of choosing healthy and low-calorie foods will be evaluated using logistic regression model with level of executive function and goal-priming intervention as the main between-group factors.
The purpose of this study is to determine the benefit of stereotaxic aspiration for patients with primary brainstem hemorrhage with the guidance of 'Zhe-er Classification'
The Hangzhou Hospital Staff Cohort (HHSC) is a prospective cohort study among staffs from three hospitals located in Hangzhou, China, including the Hangzhou First People's Hospital, Hangzhou Women's Hospital, and Hangzhou Red Cross Hospital. Participants recruitment and baseline survey including anthropometric, lifestyle and clinical measurement, as well as biological samples collection are initiated in January 2021. Recruited hospital staff are followed up every year during the medical examination organized by their employer. The primary aim of the HHSC study is to investigate the prospective associations of diet, physical activities, sleep, and other lifestyle factors with the long-term metabolic health of the hospital staffs. The secondary aim of the HHSC study is to integrate multi-omics data including genomics, metabolomics, proteomics and microbiome by a machine learning algorithm, to probe into the complex mediating roles of gene, metabolism and gut microbiota linking lifestyle factors with metabolic health.
The purpose of this study is to evaluate the clinical efficacy and safety of HLX22 in the HER2+ Locally Adanved or Metastatic Gastric Cancer as the first-line therapy.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria. The enrolled subjects will receive an intravenous infusion of HLX22/placebo and SOC(standard of care: Trastuzumab + XELOX) once every 3 weeks until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent or other reasons as specified in the protocol(whichever occurs earlier).